NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

you wrote:

Unfortunately the sample size is so small for those that did not crossover that it is unlikely to be statistically significant.
This is especially true considering this group likely includes those patients that died unexpectedly before being offered crossover and includes patients who exited to participate in other trials.

1. I am not convinced that the sample size is too small to be stat sig, as it relates to the patients who started out in the placebo group who did not cross over.
2. I think it would bode well for DCVax-L efficacy if the patients who died unexpectedly/early were patients in the placebo group and less patients dying early in the treatment group. If a patient from the placebo group dies early ... it still results in a PFS event. This would actually improve the odds of PFS reaching a 4 month variance between treatment vs placebo group.